Journal article
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol.6(1), pp.201-209
2017
Abstract
Introduction
Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild‐to‐moderate Alzheimer's disease (AD) subjects from healthy elderly control (HC) subjects.
Methods
A CSF tau/Aβ42 cutoff criteria was chosen, which distinguished the groups and maximized concordance with amyloid PET. Performance was assessed using an independent validation cohort.
Results
A tau/Aβ42 = 0.215 cutoff provided 94.8% sensitivity and 77.7% specificity. Concordance with PET visual reads was estimated at 86.9% in a ∼50% PET positive population. In the validation cohort, the cutoff demonstrated 78.4% sensitivity and 84.9% specificity to distinguish the AD and HC populations.
Discussion
A tau/Aβ42 cutoff with acceptable sensitivity and specificity distinguished HC from mild‐to‐moderate AD subjects and maximized concordance to brain amyloidosis. The defined cutoff demonstrated that CSF analysis may be useful as a surrogate to imaging assessment of AD pathology.
Details
- Title
- A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
- Authors/Creators
- Y. Mo (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)J. Stromswold (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)K. Wilson (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)D. Holder (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)C. Sur (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)O. Laterza (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)M.J. Savage (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)A. Struyk (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)P. Scheltens (Author/Creator) - Amsterdam UMC Location Vrije Universiteit AmsterdamC.E. Teunissen (Author/Creator) - Amsterdam UMC Location Vrije Universiteit AmsterdamJ. Burke (Author/Creator) - Duke UniversityS.L. Macaulay (Author/Creator) - Health Sciences and NutritionG. Bråthen (Author/Creator) - Norwegian University of Science and TechnologyS.B. Sando (Author/Creator) - Norwegian University of Science and TechnologyL.R. White (Author/Creator) - Norwegian University of Science and TechnologyC. Weiss (Author/Creator) - Luminex (United States)A. Cowes (Author/Creator) - Luminex (United States)M.M. Bush (Author/Creator) - Luminex (United States)G. DeSilva (Author/Creator) - Luminex (United States)D.G. Darby (Author/Creator) - Florey Institute of Neuroscience and Mental HealthS.R. Rainey‐Smith (Author/Creator)J. Surls (Author/Creator) - Luminex (United States)E. Sagini (Author/Creator) - Luminex (United States)M. Tanen (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)A. Altman (Author/Creator) - Luminex (United States)J. Luthman (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)M.F. Egan (Author/Creator) - Merck & Co., Inc., Rahway, NJ, USA (United States)
- Publication Details
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol.6(1), pp.201-209
- Publisher
- Elsevier Inc. on behalf of the Alzheimer’s Association
- Identifiers
- 991005543345207891
- Copyright
- © 2017 The Authors.
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
Metrics
43 File views/ downloads
67 Record Views